BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27664126)

  • 1. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
    Houédé N; Locker G; Lucas C; Parra HS; Basso U; Spaeth D; Tambaro R; Basterretxea L; Morelli F; Theodore C; Lusuardi L; Lainez N; Guillot A; Tonini G; Bielle J; Del Muro XG
    BMC Cancer; 2016 Sep; 16(1):752. PubMed ID: 27664126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data.
    Hegele A; Goebell P; Matz U; Neuhaus T
    Urol Int; 2014; 92(2):174-9. PubMed ID: 24334998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
    Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
    BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.
    Retz M; de Geeter P; Goebell PJ; Matz U; de Schultz W; Hegele A
    BMC Cancer; 2015 Jun; 15():455. PubMed ID: 26040470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
    Bambury RM; Benjamin DJ; Chaim JL; Zabor EC; Sullivan J; Garcia-Grossman IR; Regazzi AM; Ostrovnaya I; Apollo A; Xiao H; Voss MH; Iyer G; Bajorin DF; Rosenberg JE
    Oncologist; 2015 May; 20(5):508-15. PubMed ID: 25845990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
    Vaughn DJ; Srinivas S; Stadler WM; Pili R; Petrylak D; Sternberg CN; Smith DC; Ringuette S; de Wit E; Pautret V; George C
    Cancer; 2009 Sep; 115(18):4110-7. PubMed ID: 19536904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
    Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
    Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.
    Bordi P; Tiseo M; Baldari G; Buti S
    BMC Cancer; 2016 Aug; 16():626. PubMed ID: 27519420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.
    Harshman LC; Fougeray R; Choueiri TK; Schutz FA; Salhi Y; Rosenberg JE; Bellmunt J
    Br J Cancer; 2013 Nov; 109(10):2548-53. PubMed ID: 24129239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
    Castellano D; Puente J; de Velasco G; Chirivella I; López-Criado P; Mohedano N; Fernández O; García-Carbonero I; González MB; Grande E
    BMC Cancer; 2014 Oct; 14():779. PubMed ID: 25342282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
    Bellmunt J; Chang J; Pavilack-Kirker M; Cappelleri JC; Costa N; Esterberg E; Kearney M; Hitchens A; Candrilli SD; Ajmera M
    Clin Genitourin Cancer; 2023 Aug; 21(4):459-466. PubMed ID: 37149458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
    Krajewski KM; Fougeray R; Bellmunt J; Pons F; Schutz FA; Rosenberg JE; Salhi Y; Choueiri TK
    Eur J Cancer; 2012 Jul; 48(10):1495-502. PubMed ID: 22176867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
    Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R;
    Ann Oncol; 2017 Jul; 28(7):1517-1522. PubMed ID: 28419193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
    De Luca R; Profita G; Vella M; Cicero G
    Oncology; 2019; 97(6):341-347. PubMed ID: 31461721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
    Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
    BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
    Sternberg CN; Bellmunt J; Sonpavde G; Siefker-Radtke AO; Stadler WM; Bajorin DF; Dreicer R; George DJ; Milowsky MI; Theodorescu D; Vaughn DJ; Galsky MD; Soloway MS; Quinn DI;
    Eur Urol; 2013 Jan; 63(1):58-66. PubMed ID: 22917984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.